CN115254891A - Harmless treatment method capable of reducing toxicity of doramectin fungi residues - Google Patents
Harmless treatment method capable of reducing toxicity of doramectin fungi residues Download PDFInfo
- Publication number
- CN115254891A CN115254891A CN202210774400.2A CN202210774400A CN115254891A CN 115254891 A CN115254891 A CN 115254891A CN 202210774400 A CN202210774400 A CN 202210774400A CN 115254891 A CN115254891 A CN 115254891A
- Authority
- CN
- China
- Prior art keywords
- doramectin
- toxicity
- harmless treatment
- reducing
- baking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 title claims abstract description 52
- 229960003997 doramectin Drugs 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 40
- 230000001988 toxicity Effects 0.000 title claims abstract description 30
- 231100000419 toxicity Toxicity 0.000 title claims abstract description 30
- 241000233866 Fungi Species 0.000 title claims abstract description 16
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims abstract description 33
- 230000001580 bacterial effect Effects 0.000 claims abstract description 31
- 239000000463 material Substances 0.000 claims abstract description 15
- 238000010257 thawing Methods 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims description 30
- 239000007857 degradation product Substances 0.000 claims description 16
- 230000007059 acute toxicity Effects 0.000 claims description 12
- 231100000403 acute toxicity Toxicity 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 8
- 239000007791 liquid phase Substances 0.000 claims description 8
- 229910052573 porcelain Inorganic materials 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 238000005057 refrigeration Methods 0.000 claims description 3
- 239000002893 slag Substances 0.000 abstract description 4
- 239000013067 intermediate product Substances 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 2
- 239000005660 Abamectin Substances 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229950008167 abamectin Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 241000238421 Arthropoda Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical group C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000004540 pour-on Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
- B09B3/30—Destroying solid waste or transforming solid waste into something useful or harmless involving mechanical treatment
- B09B3/35—Shredding, crushing or cutting
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
- B09B3/30—Destroying solid waste or transforming solid waste into something useful or harmless involving mechanical treatment
- B09B3/38—Stirring or kneading
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
- B09B—DISPOSAL OF SOLID WASTE NOT OTHERWISE PROVIDED FOR
- B09B3/00—Destroying solid waste or transforming solid waste into something useful or harmless
- B09B3/40—Destroying solid waste or transforming solid waste into something useful or harmless involving thermal treatment, e.g. evaporation
Landscapes
- Engineering & Computer Science (AREA)
- Environmental & Geological Engineering (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a harmless treatment method capable of reducing the toxicity of doramectin fungi residues. The method comprises the following steps: 1) Refrigerating and storing doramectin bacterial residues, and performing thawing pretreatment; 2) The thawed mushroom dregs are stirred to be loose, and meanwhile, the mycelium is uniformly damaged; 3) And (3) baking the material obtained in the step 2) to degrade the material, wherein the baking temperature is set to be 160 ℃, 180 ℃, 200 ℃ and 220 ℃ respectively. The method can obviously reduce the toxicity of the intermediate product generated by harmless treatment of the doramectin bacterial slag, is simple and quick to operate, and can effectively reduce the cost of the harmless treatment.
Description
Technical Field
The invention belongs to the technical field of harmless treatment of antibiotic bacterial residues, and particularly relates to a harmless treatment method capable of reducing toxicity of doramectin bacterial residues.
Background
At present, doramectin is recognized as one of the most excellent internal and external antiparasitic drugs in avermectin groups, and has good killing effect on nematodes in vivo and in vitro and arthropods in vitro. Doramectin is a second generation product of abamectin, and the synthesis mechanism of doramectin is formed by introducing a cyclohexane group into the 25 th position C of the abamectin. Doramectin has extremely low solubility in water, is a fat-soluble drug, and can be dissolved in various organic solvents such as dimethyl sulfoxide, ethyl acetate, propylene glycol, dichloromethane, dimethylformamide and the like. Due to the characteristics of doramectin, such as poor water solubility, and the addition of a cosolvent for assisting in dissolving medicaments in the production of a medicament injection, the use dosage form of doramectin is mainly injection and a special pour-on agent for cattle.
The realization of harmless treatment of the bacterial residues is an essential key step for realizing the continuous development of the antibiotic bacterial residues, meanwhile, the toxicity of degradation products generated after the harmless post-treatment cannot be ignored, and attention should be paid to the reduction of the biological toxicity.
However, doramectin is an antibiotic which is gradually widely used, and due to the use of the dosage form, part of the medicament enters the environment and causes non-negligible harm to human beings and the environment. However, there are only few reports on the harmless treatment mode of doramectin bacterial residues, and related researches on the toxicity of the treated first-stage degradation products are lacked.
Disclosure of Invention
Aiming at the technical problems, the invention provides a harmless treatment method capable of reducing the toxicity of doramectin bacterial residues, the method can obviously reduce the toxicity of an intermediate product generated by harmless treatment of doramectin bacterial residues, the method is simple and rapid to operate, and the cost of the harmless treatment can be effectively reduced.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention discloses a harmless treatment method capable of reducing toxicity of doramectin fungi residues, which comprises the following steps:
1) Refrigerating and storing doramectin bacterial residues, and performing thawing pretreatment;
2) The thawed mushroom dregs are stirred to be loose, and meanwhile, the mycelium is uniformly damaged;
3) Baking the material obtained in the step 2) to degrade the material, wherein the baking temperature is set to any one of 160 ℃, 180 ℃, 200 ℃ and 220 ℃.
Preferably, the refrigeration temperature of the step 1) is 4 ℃, and the thawing is carried out at room temperature.
Preferably, the step 2) is: and (3) performing primary stirring on the thawed mushroom dregs by adopting a tissue mincing machine at the stirring speed of 800-1000 rpm so as to destroy mushroom clusters of the mushroom dregs, and performing secondary stirring at the stirring speed of 600-800 rpm by reducing the rotating speed so as to loosen the mushroom dregs and uniformly destroy the mycelia.
Preferably, the step 3) is: flatly paving the materials obtained in the step 2) in a loose and uniform manner in a porcelain boat, placing the porcelain boat in the center of the muffle furnace when the temperature of the muffle furnace rises to the baking temperature, closing the furnace door of the muffle furnace, isolating oxygen for baking, and taking out the sample immediately after the baking time is over.
Preferably, the baking time is 120min, most preferably 180 ℃ or 200 ℃.
Preferably, the method further comprises the step 4): and (3) carrying out acute toxicity evaluation on the doramectin bacterial residue degradation product in the sample obtained after the treatment in the step 3).
Preferably, the step 4) is: analyzing the sample obtained after the treatment in the step 3) by using an ultrahigh pressure liquid phase and ultrahigh resolution liquid chromatograph-mass spectrometer so as to evaluate the acute toxicity of the doramectin bacterial residue degradation product.
Compared with the prior art, the invention has the advantages and positive effects that: the method has the advantages that the whole treatment process is simple and easy to operate, the energy consumption is low, the cost is low, the treatment process can be carried out in a closed environment, irritant and toxic and harmful gases cannot be generated, and secondary pollution to the environment in the harmless treatment process can be avoided. The method converts the mushroom dreg waste into a treatment product with use value through a simple and feasible harmless treatment process, greatly reduces the toxicity of an intermediate product generated by the harmless treatment of the mushroom dreg, and can effectively solve the problem of environmental pollution caused by the doramectin mushroom dreg.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the provided drawings without creative efforts.
FIG. 1 is a schematic diagram of the primary degradation products after baking process treatment at different baking temperatures;
FIG. 2 is a graph showing the results of acute toxicity analysis tests of the primary degradation products after baking treatment at different baking temperatures.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be obtained by a person skilled in the art without making any creative effort based on the embodiments in the present invention, belong to the protection scope of the present invention.
A harmless treatment method capable of reducing toxicity of doramectin fungi residues comprises the following steps:
1) Refrigerating and storing untreated fresh doramectin bacterial residues, and performing unfreezing pretreatment;
2) The thawed mushroom dregs are stirred to be loose, and meanwhile, the mycelium is uniformly damaged;
3) Baking the material obtained in the step 2) to degrade the material, wherein the baking temperature is 160 ℃, 180 ℃, 200 ℃ or 220 ℃.
By adopting the method, the toxicity of the primary degradation product obtained after the doramectin bacterial residues are subjected to harmless treatment can be effectively reduced, and the toxicity of the primary degradation product obtained after the doramectin bacterial residues are baked can be remarkably reduced by treating the bacterial residues according to a specific baking temperature. The whole treatment process of the method is simple and easy to operate, the energy consumption is low, the cost is low, the treatment process can be carried out in a closed environment, irritant, toxic and harmful gases cannot be generated, and secondary pollution to the environment in a harmless treatment process can be avoided.
Specifically, the refrigeration temperature in the step 1) is 4 ℃, and the thawing is carried out at room temperature.
Specifically, in order to ensure the crushing effect, the step 2) is as follows: and (3) stirring the unfrozen mushroom dregs for the first time by a tissue stirring machine at the stirring speed of 800-1000 rpm for 2-3 min to destroy mushroom mycelium masses, and stirring for the second time at the stirring speed of 600-800 rpm for 0.5-1 min to loosen the mushroom dregs and uniformly destroy the mycelia. The untreated doramectin bacterial slag has low water content of 6.15-6.5%, is stirred in a tissue mincing machine at the rotating speed of 800-1000 rpm for the first time, and is instantaneously stirred at high speed, so that partial loose doramectin bacterial slag is adhered to the wall of an instrument, and partial mycelial clusters cannot be completely damaged, and then the rotating speed is reduced at the stirring speed of 600-800 rpm for the second time, so that the mycelium is more uniformly damaged, and the bacterial slag is more uniformly loosened.
Wherein, in order to ensure the baking treatment effect, the step 3) is as follows: and (3) flatly and loosely paving the materials obtained in the step 2) in a porcelain boat, placing the porcelain boat in the center of the muffle furnace when the temperature of the muffle furnace rises to the baking temperature, closing the muffle furnace door, isolating oxygen for baking, and taking out the sample immediately after the baking time is over.
Wherein, in order to ensure that the toxicity of the product obtained by treatment is obviously reduced, the baking process condition needs to be controlled, and the baking time is 120min; the chemical structures of the products obtained by adopting the baking temperatures are respectively shown in figure 1, the samples treated at four different baking temperatures are subpackaged for treatment, the ultra-high pressure liquid phase ultra-high resolution liquid chromatograph-mass spectrometer is used for analyzing and testing doramectin bacterial residues subjected to harmless treatment by a baking method, the acute toxicity analysis test result of the obtained products is shown in figure 2, and from figure 2, the toxicity of other products is greatly reduced except that the toxicity of the product Q (the product treated at 220 ℃) and the toxicity of the product A (the product treated at 160 ℃). The preferred baking temperature for this embodiment is 180 ℃ or 200 ℃.
Wherein, in order to accurately determine the processing effect of the method, the method further comprises the following step 4): and (3) carrying out acute toxicity evaluation on the doramectin bacterial residue degradation product in the sample obtained after the treatment in the step 3).
Specifically, the step 4) is as follows: analyzing the sample obtained after the treatment in the step 3) by using an ultrahigh pressure liquid phase and ultrahigh resolution liquid chromatograph-mass spectrometer so as to evaluate the acute toxicity of the doramectin bacterial residue degradation product.
Example 1
A harmless treatment method capable of reducing toxicity of doramectin fungi residues is characterized by comprising the following steps:
1) Refrigerating doramectin bacterial residues at 4 ℃, and then performing unfreezing pretreatment at room temperature;
2) Stirring the thawed mushroom dregs for the first time by a tissue mincing machine at the stirring speed of 800rpm for 3min so as to destroy mushroom mycelium clusters, and stirring for the second time at the stirring speed of 600rpm for 1min so as to loosen the mushroom dregs and uniformly destroy the mycelium;
3) Baking the material obtained in the step 2) for degradation, wherein the baking temperature is 160 ℃, the baking time is 120min, and the obtained product is shown as A in figure 1;
4) Analyzing the sample obtained after the treatment in the step 3) by using an ultrahigh pressure liquid phase and ultrahigh resolution liquid chromatography-mass spectrometer to evaluate the acute toxicity of the doramectin bacterial residue degradation product, wherein the analysis result is shown as A in figure 2.
Example 2
A harmless treatment method capable of reducing toxicity of doramectin fungi residues is characterized by comprising the following steps:
1) Refrigerating doramectin bacterial residues at 4 ℃, and then performing unfreezing pretreatment at room temperature;
2) Stirring the thawed mushroom dregs for the first time by a tissue mincing machine at the stirring speed of 1000rpm for 2min so as to destroy mushroom mycelium clusters, and stirring for the second time at the stirring speed of 800rpm by reducing the rotating speed for 0.5min so as to loosen the mushroom dregs and uniformly destroy the mycelia;
3) Baking the material obtained in the step 2) for degradation, wherein the baking temperature is 180 ℃, the baking time is 120min, and the obtained product is shown as H, E, F and G in figure 1;
4) Analyzing the sample obtained after the treatment in the step 3) by using an ultrahigh pressure liquid phase and ultrahigh resolution liquid chromatography-mass spectrometer to evaluate the acute toxicity of the doramectin bacterial residue degradation product, wherein the analysis results are shown as H, E, F and G in figure 2.
Example 3
A harmless treatment method capable of reducing toxicity of doramectin fungi residues is characterized by comprising the following steps:
1) Refrigerating doramectin mushroom dregs at 4 ℃, and then performing unfreezing pretreatment at room temperature;
2) Stirring the thawed mushroom dregs for the first time by a tissue mincing machine at the stirring speed of 900rpm for 2.5min to destroy mushroom mycelium clusters, and stirring for the second time at the stirring speed of 700rpm by reducing the rotating speed for 1min to loosen the mushroom dregs and uniformly destroy the mycelium;
3) Baking the material obtained in the step 2) for degradation, wherein the baking temperature is 200 ℃, the baking time is 120min, and the obtained product is shown as K and J in figure 1;
4) Analyzing the sample obtained after the treatment in the step 3) by using an ultrahigh pressure liquid phase and ultrahigh resolution liquid chromatograph-mass spectrometer to evaluate the acute toxicity of the doramectin bacterial residue degradation product, wherein the analysis results are shown as K and J in figure 2.
Example 4
A harmless treatment method capable of reducing toxicity of doramectin fungi residues is characterized by comprising the following steps:
1) Refrigerating doramectin mushroom dregs at 4 ℃, and then performing unfreezing pretreatment at room temperature;
2) Stirring the thawed mushroom dregs for the first time at the stirring speed of 1000rpm by using a tissue blender for 2min to destroy mushroom mycelium clusters, and stirring for the second time at the stirring speed of 800rpm by reducing the rotating speed for 0.5min to loosen the mushroom dregs and uniformly destroy the mycelia;
3) Baking the material obtained in the step 2) for degradation, wherein the baking temperature is 220 ℃, the baking time is 120min, and the obtained product is shown as Q, P and O in figure 1;
4) Analyzing the sample obtained after the treatment in the step 3) by using an ultrahigh pressure liquid phase and ultrahigh resolution liquid chromatography-mass spectrometer to evaluate the acute toxicity of the doramectin bacterial residue degradation product, wherein the analysis results are shown as Q, P and O in figure 2.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
Claims (8)
1. A harmless treatment method capable of reducing toxicity of doramectin fungi residues is characterized by comprising the following steps:
1) Refrigerating and storing doramectin bacterial residues, and performing thawing pretreatment;
2) The thawed mushroom dregs are stirred to loosen the mushroom dregs and uniformly destroy the mycelia;
3) Baking the material obtained in the step 2) to degrade the material, wherein the baking temperature is set to any one of 160 ℃, 180 ℃, 200 ℃ and 220 ℃.
2. The method for detoxifying according to claim 1 wherein said step 1) is carried out at a refrigeration temperature of 4 ℃ and thawing is carried out at room temperature.
3. The harmless treatment method for reducing the toxicity of doramectin fungi residues as claimed in claim 1, wherein the step 2) is as follows: and (3) performing primary stirring on the thawed mushroom dregs by adopting a tissue mincing machine at the stirring speed of 800-1000 rpm so as to destroy mushroom clusters of the mushroom dregs, and performing secondary stirring at the stirring speed of 600-800 rpm by reducing the rotating speed so as to loosen the mushroom dregs and uniformly destroy the mycelia.
4. The harmless treatment method for reducing the toxicity of doramectin fungi residues as claimed in claim 1, wherein the step 3) is as follows: and (3) flatly and loosely paving the materials obtained in the step 2) in a porcelain boat, placing the porcelain boat in the center of the muffle furnace when the temperature of the muffle furnace rises to the baking temperature, closing the muffle furnace door, isolating oxygen for baking, and taking out the sample immediately after the baking time is over.
5. The harmless treatment method for reducing the toxicity of doramectin fungi residues according to claim 4, wherein the baking time is 120min.
6. The harmless treatment method for reducing the toxicity of doramectin fungi residues according to claim 1, wherein the baking temperature is 180 ℃ or 200 ℃.
7. The harmless treatment method for reducing the toxicity of doramectin fungi residues according to claim 1, which is characterized by further comprising the step 4): and (3) carrying out acute toxicity evaluation on the doramectin bacterial residue degradation product in the sample obtained after the treatment in the step 3).
8. The harmless treatment method for reducing the toxicity of doramectin fungi residues according to claim 7, wherein the step 4) is as follows: analyzing the sample obtained after the treatment in the step 3) by using an ultrahigh pressure liquid phase and ultrahigh resolution liquid chromatograph-mass spectrometer so as to evaluate the acute toxicity of the doramectin bacterial residue degradation product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210774400.2A CN115254891A (en) | 2022-07-01 | 2022-07-01 | Harmless treatment method capable of reducing toxicity of doramectin fungi residues |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210774400.2A CN115254891A (en) | 2022-07-01 | 2022-07-01 | Harmless treatment method capable of reducing toxicity of doramectin fungi residues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115254891A true CN115254891A (en) | 2022-11-01 |
Family
ID=83762831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210774400.2A Pending CN115254891A (en) | 2022-07-01 | 2022-07-01 | Harmless treatment method capable of reducing toxicity of doramectin fungi residues |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115254891A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1764489A (en) * | 2003-01-22 | 2006-04-26 | 维克凯斯工业有限公司 | A method for neutralization of toxin agents, pesticides and their hydrolysates, and a reagent for it |
| CN104690075A (en) * | 2015-03-13 | 2015-06-10 | 江西绿环生物科技有限公司 | Carcass innocent treatment method |
| US20170042923A1 (en) * | 2015-08-10 | 2017-02-16 | Lehigh University | Reduced toxicity molecular conjugates of anti-fungal agents |
| CN109678613A (en) * | 2019-02-26 | 2019-04-26 | 焦作健康元生物制品有限公司 | A kind of method that efficient cephalosporin dreg prepares organic fertilizer |
| CN112408685A (en) * | 2020-11-25 | 2021-02-26 | 上海化工研究院有限公司 | Method for removing residual antibiotics in antibiotic dreg slurry |
| CN114535269A (en) * | 2022-01-19 | 2022-05-27 | 武汉回盛生物科技股份有限公司 | Harmless treatment method for antibiotic bacterium residues and application thereof |
-
2022
- 2022-07-01 CN CN202210774400.2A patent/CN115254891A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1764489A (en) * | 2003-01-22 | 2006-04-26 | 维克凯斯工业有限公司 | A method for neutralization of toxin agents, pesticides and their hydrolysates, and a reagent for it |
| CN104690075A (en) * | 2015-03-13 | 2015-06-10 | 江西绿环生物科技有限公司 | Carcass innocent treatment method |
| US20170042923A1 (en) * | 2015-08-10 | 2017-02-16 | Lehigh University | Reduced toxicity molecular conjugates of anti-fungal agents |
| CN109678613A (en) * | 2019-02-26 | 2019-04-26 | 焦作健康元生物制品有限公司 | A kind of method that efficient cephalosporin dreg prepares organic fertilizer |
| CN112408685A (en) * | 2020-11-25 | 2021-02-26 | 上海化工研究院有限公司 | Method for removing residual antibiotics in antibiotic dreg slurry |
| CN114535269A (en) * | 2022-01-19 | 2022-05-27 | 武汉回盛生物科技股份有限公司 | Harmless treatment method for antibiotic bacterium residues and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kumar et al. | Fucoidan–A α-d-glucosidase inhibitor from Sargassum wightii with relevance to type 2 diabetes mellitus therapy | |
| Taillandier et al. | The role of ubiquitin–proteasome-dependent proteolysis in the remodelling of skeletal muscle | |
| Aoki et al. | A model of port-site metastases of gallbladder cancer: the influence of peritoneal injury and its repair on abdominal wall metastases | |
| CN115254891A (en) | Harmless treatment method capable of reducing toxicity of doramectin fungi residues | |
| Olteanu et al. | The effects of chitosan and low dose dexamethasone on extrahepatic cholestasis after bile duct ligation in Wistar rats | |
| KR101623196B1 (en) | Butchery disposal method of animal | |
| CN106635803A (en) | Preparation and preservation method of anammox bacterium dry microbial inoculum | |
| WO1999056698A3 (en) | Treatment of celiac disease | |
| KR20200119088A (en) | Method for Preparation of Chitosan Derived from Soldier Fly | |
| Dixon et al. | Bacteriological and histological studies of the small intestine of rats treated with mecamylamine | |
| Khatimah et al. | ANALISIS AL-QUR’AN TERHADAP MENTAL HEALTH ORANG TUA:(Fenomena Tindakan Orang Tua Terhadap Pembunuhan Anak Di Indonesia Pada Bulan Maret-April 2022) | |
| CN105241741A (en) | Pretreatment method for detecting metal elements in kapok powder | |
| CN113122540A (en) | RNAi target gene capable of killing grubs efficiently and application of RNAi target gene | |
| CN104473967A (en) | Pig gall powder preparing process | |
| Verma et al. | Structural elucidation of bioactive secondary metabolites from endophytic fungus | |
| Yu et al. | Risk factors for prolongation of ileostomy closure operation. | |
| CN105032889A (en) | Boiling treatment method and device for organic fresh food and kitchen garbage | |
| CN107296007B (en) | Construction method of animal model of metacercaria pulmonary cyst disease of sandrat afternoon | |
| Hu et al. | Nematicidal Streptomyces against Meloidogyne incognita by hydrosoluble macromolecules | |
| CN110637908A (en) | Wall breaking method of moringa oleifera leaves and preparation method of fermented moringa oleifera leaf tea | |
| CN112973928B (en) | Method and apparatus for treating carcasses using microwave drying and air flow milling | |
| CN104208087B (en) | A kind of taxol composite nano-emulsion and preparation method thereof | |
| CN109169720A (en) | Prevent and treat Citrus Huanglongbing pathogen medicament and preparation method thereof | |
| 金郡潮 et al. | Study on the Dyeing Behaviors of Low Temperature Glow Discharge Treated Wool | |
| Foreman et al. | Investigations on the Prevention of Nuisances arising from Flies and Putrefaction1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |